Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 2/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922661 | 0.87 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL28799029 | 0.85 | ALDH1A1 (0.49) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL1232308 | 0.85 | MAPT (0.49) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL3152935 | 0.85 | GSK3B (0.53) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL3155889 | 0.85 | ALDH1A1 (0.49) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL21765854 | 0.83 | KMT2A (0.43) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8751720 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL3146418 | 0.82 | POLB (0.49) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL3936872 | 0.82 | MAPT (0.60) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL11002701 | 0.82 | ALDH1A1 (0.55) | MAPTALDH1A1SMN1; SMN2L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2440559-B1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-102482277-A | Egfr inhibitors and methods of treating disorders | DANA FARBER CANCER INST INC | 2012-05-30 | — | — | CN | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2440559-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-1200435-B1 | PURINE DERIVATIVES INHIBITORS OF TYROSINE PROTEIN KINASE SYK | NOVARTIS AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6589950-B1 | Treatment of inflammatory or obstructive airways disease for respiratory system disorders | NOVARTIS AG (CH) | 2003-07-08 | — | — | US | disclosed |
| EP-1200435-A1 | PURINE DERIVATIVES INHIBITORS OF TYROSINE PROTEIN KINASE SYK | Novartis AG (CH) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009134-A1 | PURINE DERIVATIVES INHIBITORS OF TYROSINE PROTEIN KINASE SYK | NOVARTIS AG (CH) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | MAPT 2615/4885ALDH1A1 3638/4885SMN1; SMN2 4765/4885 |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | EGFR, ERBB2, ERBB4 | MAPT 2615/4885ALDH1A1 3638/4885SMN1; SMN2 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.